Compare NEXN & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NEXN | CBIO |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.2M | 389.7M |
| IPO Year | 2021 | N/A |
| Metric | NEXN | CBIO |
|---|---|---|
| Price | $5.66 | $9.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $12.00 | ★ $27.17 |
| AVG Volume (30 Days) | ★ 357.9K | 167.9K |
| Earning Date | 03-04-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 237.45 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $376,353,000.00 | N/A |
| Revenue This Year | $5.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.00 | ★ N/A |
| Revenue Growth | ★ 7.80 | N/A |
| 52 Week Low | $5.72 | $9.43 |
| 52 Week High | $12.60 | $21.40 |
| Indicator | NEXN | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 34.27 | 31.51 |
| Support Level | $5.81 | $9.43 |
| Resistance Level | $6.39 | $14.71 |
| Average True Range (ATR) | 0.28 | 1.23 |
| MACD | -0.01 | -0.32 |
| Stochastic Oscillator | 8.33 | 5.61 |
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.